CORVALLIS, OR--(Marketwire - August 04, 2008) - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that Dr. Leslie Hudson, CEO, will present an update on the transitioning of AVI from an antisense pioneer into an RNA-based drug discovery and development company. The corporate overview will include an update on AVI’s clinical trials in Duchenne muscular dystrophy, its biodefense projects -- which include significant data from our ongoing Ebola and Marburg virus programs -- its partnership with Cook Medical in the development of a drug eluting stent for cardiovascular restenosis and the company’s renewed focus on partnership and collaboration to develop other promising applications and programs within AVI.
